According to the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) Obesity Clinical Practice Guidelines, weight loss medications should be offered as chronic treatment along with lifestyle modifications to patients with obesity when the potential benefits outweigh the risks
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management
However, seek immediate medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Signs of thyroid tumors: lump in the neck, hoarseness, difficulty swallowing, or shortness of breath Symptoms of severe hypoglycemia (when used with insulin or sulfonylureas): confusion, dizziness, severe sweating, or loss of consciousness Signs of kidney problems: decreased urination, swelling in legs or feet, unusual fatigue Severe allergic reactions: rash, itching, severe dizziness, difficulty breathing Storage and disposal: Store unused pens in the refrigerator (36F to 46F)
Neither deviation is dangerous at this early phase, but consistency matters over time
It was found that there was no significant difference in weight modification between the use of Tirzepatide at a dosage of 15 mg once weekly and Semaglutide at a dosage of 1 mg once a week
